However, a recent study depicted that the size of FLT3-ITD mutations has no prognostic impact on the overall survival, relapse, or complete remission rate among newly diagnosed AML patients treated with chemotherapy [73]. The gene discussed is FLT3; the disease is acute myeloid leukemia.